Renaissance Technologies LLC Grows Position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Renaissance Technologies LLC boosted its position in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 160.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 107,062 shares of the medical research company’s stock after purchasing an additional 65,984 shares during the period. Renaissance Technologies LLC owned about 0.43% of Accelerate Diagnostics worth $128,000 as of its most recent SEC filing.

Separately, Geode Capital Management LLC increased its stake in shares of Accelerate Diagnostics by 6.9% during the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after buying an additional 8,777 shares during the period. 17.14% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics Price Performance

Shares of NASDAQ AXDX opened at $0.49 on Wednesday. Accelerate Diagnostics, Inc. has a 1-year low of $0.47 and a 1-year high of $2.09. The business has a fifty day moving average price of $0.78 and a 200 day moving average price of $1.20. The stock has a market capitalization of $12.35 million, a P/E ratio of -0.17 and a beta of 0.22.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings results on Thursday, March 20th. The medical research company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.13. The firm had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $3.00 million. As a group, equities research analysts anticipate that Accelerate Diagnostics, Inc. will post -2.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Accelerate Diagnostics in a research note on Sunday. They issued a “hold” rating for the company.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.